

IN THE CLAIMS:

1-37. (Canceled)

38. (Previously presented) A composition comprising modified GPI molecule or derivative or equivalent thereof which induces an immune response directed to a micro-organism GPI inositolglycan domain but is incapable of inducing an immune response directed to a lipidic domain of said GPI.

39-53. (Canceled)

54. (Previously presented) A composition according to claim 38, wherein said modified GPI molecule comprises insufficient lipidic domain to induce or elicit an immune response directed to a GPI lipid domain.

55. (Previously presented) A composition according to claim 38 or 54, wherein said modified GPI molecule is the inositolglycan domain portion of GPI or a derivative or equivalent thereof.

56. (Previously presented) A composition according to claim 55, wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

57. (Previously presented) A composition according to claim 56, wherein said parasite is Plasmodium.

58. (Previously presented) A composition according to claim 57, wherein said Plasmodium is *P. falciparum*.

59. (Currently amended) A composition according to claim 54 or 58, wherein said GPI inositolglycan domain comprises the structure ~~ethanolamine phosphate (Man α 1,2) Man α~~

~~1,2Man α 1,6Man α 1,4GlcN-myo-inositol phosphoglycerol ethanolamine-phosphate-~~
~~(Man α 1,2)- Man α 1,2 Man α 1,6 Man α 1,4 GlcN-myo-inositol phosphoglycerol~~ or a derivative or
equivalent thereof.

60. (Currently amended) A composition according to claim 54 or 58, wherein said
GPI inositolglycan domain comprises the structure

~~X1—X2—X3—X4—ethanolamine-phosphate-(Man α 1,2)-Man α 1,2Man α 1,6Man α 1,~~
~~4GlcN-myo-inositol phosphoglycerol~~ X1—X2—X3—X4-ethanolamine-phosphate-(Man α 1,2)-
Man α 1,2Man α 1,6Man α 1,4GlcN-myo-inositol phosphoglycerol

wherein X1, X2, X3 and X4 are any 4 amino acids, or derivative or equivalent of said
GPI ~~inositoiglycan~~ inositolglycan domain.

61. (Currently amended) A composition according to claim 54 or 58, wherein said
GPI inositolglycan domain comprises the structure

EtN-P-[M α 2]M α 2 M α 6 M α 4G α 6Ino
EtN-P-[M α 2][G]M α 2 M α 6 M α 4G α 6Ino
~~EtN-P-[M α 2][X]Me-2 M α 6 M α 4G α 6Ino~~ EtN-P-[M α 2][X]M α 2M α 6M α 4G α 6Ino
~~EtN-P-[M α 2][EtN-P]M α 2 Me6 M α 4G α 6Ino~~ EtN-P-[M α 2][EtN-P]M α 2M α 6
M α 4G α 6Ino

EtN-P-M α 2 M α 6 M α 4G

M α 2 M α 6 M α G

EtN-P-M α 2 M α 6 M

~~EtN-P-[Me-2]-(G)M α 2 M α 6 M α 4G~~ EtN-P-[M α 2][G]M α 2 M α 6 M α 4G

~~EtN-P-[M α 2][X]M α 2 M α 6 M α 4G~~ EtN-P-[M α 2][X]M α 2 M α 6 M α 4G

EtN-P-[M α 2][EtN-P]M α 2 M α 6 M α 4G

M α 2 [M α 2][G]M α 2 M α 6 M α 4G

~~M α 2 [M α 2][X]M α 2 M α 6 M α 4G~~ M α 2 [M α 2][X]M α 2 M α 6 M α 4G

M α 2 [M α 2][EtN-P]M α 6 M α 4G

~~M α 6 M α 4G α 6Ino~~ M α 6 M α 4G α 6Ino

~~Mex2 Ma6 Ma4Gu6Ino~~ Ma2 Ma6 Ma4Ga6Ino
~~Ma2 {Ma2}Ma6 Ma4Ga6Ino~~ Ma2 [Ma2]Ma6 Ma4Ga6Ino
~~Mei2 {Ma2}[G]Mei6 Ma4Ga6Ino~~ Ma2 [Ma2][G]Ma6 Ma4Ga6Ino
~~Ma2 [Ma2][X]Ma6 Ma4Ga6Ino~~
~~EtN-P-[Ma2][G]Ma2 Ma6 M~~ EtN-P-[Ma2][G]Ma2 Ma6 M
~~EtN-P-[Ma2][X]Ma2 Mu6 M~~ EtN-P-[Ma2][X]Ma2 Ma6 M
~~EtN-P-[Me2]{EtN-P}Ma2 Ma6 M~~ EtN-P-[Ma2][EtN-P]Ma2 Ma6 M
~~Ma2 {Ma2}[G]Ma2 Mez6 M~~ Ma2 [Ma2][G]Ma2 Ma6 M
~~Ma2 [Ma2][X]Ma2 Ma6 M~~
~~Ma2 {Ma2}{EtN-P}Ma6 M~~ Ma2 [Ma2][EtN-P]Ma6 M
~~Ma2 Ma6 M~~
~~Ma6 Ma4G~~
~~EtN-P-[Ma2] [G]Ma2 M~~
~~EtN-P-[Mu2]{X}Mex2 M~~ EtN-P-[Ma2][X]Ma2 M
~~EtN-P-[Ma2]{EtN-P}Mi2 M~~ EtN-P-[Ma2][EtN-P]Ma2 M

or derivative or equivalent thereof wherein EtN is ethanolamine, P is phosphate, M is ~~marmose~~ mannose, G is non-N-acetylated glucosamine, [G] is any non-N-acetylated hexosamine, ~~me~~ Ino is inositol or inositol-phosphoglycerol, [X] is any other substitute, α represent α -linkages which may be substituted with β -linkages wherever required, and numeric values represent positional linkages which may be substituted with any other positional linkages as required.